FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523528293> ?p ?o ?g. }

• W2523528293 abstract "Dry eye disease (DED) is multifactorial, affecting 5–34 % of the global adult population and reducing quality of life. The artificial tears or lubricants are the therapy most used for the treatment of DED, due to their low side effect profile, which attempt to modify the properties of the tear film. The aim of the present study was to evaluate the clinical efficacy of a fixed combination of xanthan gum and chondroitin sulfate preservative free on the ocular surface of patients with dry eye disease during 60 days of intervention. A phase III, double-blind, masked, controlled, multicenter, clinical trial of 148 subjects, randomized to either a fixed combination of xanthan gum 0.09 % and chondroitin sulfate 0.1 % (XG/CS) ophthalmic solution (n = 76) or a fixed combination of polyethylene glycol 400 0.4 % and propylene glycol 0.3 % (PEG/PG) (n = 72). Subjects self-dosed four times daily during 60 days. Follow-up was set on days 2, 7, 15, 30 and 60. Assessments of anterior/posterior segment ocular signs were performed. The outcome measures included Schirmer test, tear film break-up time and OSDI score. Security variables included intraocular pressure, lisamine green and fluorescein ocular surface stains. The primary efficacy endpoints were similar between groups at baseline. After intervention time Schirmer test increased in both groups compared to baseline, XG/CS (6.4 ± 2.2 vs 11.0 ± 6.6; p = 0.002) and PEG/PG (6.5 ± 2.5 vs 10.5 ± 5.6; p = 0.019) respectively. Similar results were reported in the tear film break-up time in XG/CS (5.5 ± 2.1 vs 7.4 ± 2.9; p = 0.027) and PEG/PG (5.2 ± 2.0 vs 7.4 ± 2.7; p = 0.046) respectively. The OSDI score decreased to normal values in both groups, XG/CS (19.3 ± 7.4 vs 7.3 ± 5.9; p = 0.001) and PEG/PG (19.3 ± 7.5 vs 7.9 ± 8.2; p = 0.001) respectively. There was no significant difference between treatments for any parameter. Moreover, both groups decreased the presence of burning sensation, tearing, foreign body sensation, conjunctival hyperemia and photophobia. The adverse events were not related to the interventions. Xanthan gum/chondroitin sulfate preservative free showed similar clinical efficacy, evaluated with OSDI score, TBUT and Schirmer test compared to polyethylene glycol/propylene glycol in the treatment of dry eye disease. ClinicalTrials.gov: NCT01657253 . Date of registration May 19, 2014." @default.
• W2523528293 created "2016-09-30" @default.
• W2523528293 creator A5006813585 @default.
• W2523528293 creator A5016476418 @default.
• W2523528293 creator A5021512769 @default.
• W2523528293 creator A5026900677 @default.
• W2523528293 creator A5031939021 @default.
• W2523528293 creator A5049009815 @default.
• W2523528293 creator A5062529728 @default.
• W2523528293 creator A5062764108 @default.
• W2523528293 creator A5066739292 @default.
• W2523528293 date "2016-09-20" @default.
• W2523528293 modified "2023-09-26" @default.
• W2523528293 title "Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial" @default.
• W2523528293 cites W147809131 @default.
• W2523528293 cites W1522561016 @default.
• W2523528293 cites W1579162790 @default.
• W2523528293 cites W1927941125 @default.
• W2523528293 cites W1978382032 @default.
• W2523528293 cites W1985438751 @default.
• W2523528293 cites W1994739407 @default.
• W2523528293 cites W2012127843 @default.
• W2523528293 cites W2013525770 @default.
• W2523528293 cites W2018452537 @default.
• W2523528293 cites W2024921065 @default.
• W2523528293 cites W2027780020 @default.
• W2523528293 cites W2038610061 @default.
• W2523528293 cites W2045750874 @default.
• W2523528293 cites W2051172714 @default.
• W2523528293 cites W2065229096 @default.
• W2523528293 cites W2070586076 @default.
• W2523528293 cites W2087758686 @default.
• W2523528293 cites W2108622238 @default.
• W2523528293 cites W2127448856 @default.
• W2523528293 cites W2129689791 @default.
• W2523528293 cites W2152024553 @default.
• W2523528293 cites W2156627811 @default.
• W2523528293 cites W2160627395 @default.
• W2523528293 cites W2735954633 @default.
• W2523528293 doi "https://doi.org/10.1186/s12886-016-0343-9" @default.
• W2523528293 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5028962" @default.
• W2523528293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27645318" @default.
• W2523528293 hasPublicationYear "2016" @default.
• W2523528293 type Work @default.
• W2523528293 sameAs 2523528293 @default.
• W2523528293 citedByCount "11" @default.
• W2523528293 countsByYear W25235282932018 @default.
• W2523528293 countsByYear W25235282932019 @default.
• W2523528293 countsByYear W25235282932020 @default.
• W2523528293 countsByYear W25235282932021 @default.
• W2523528293 countsByYear W25235282932022 @default.
• W2523528293 countsByYear W25235282932023 @default.
• W2523528293 crossrefType "journal-article" @default.
• W2523528293 hasAuthorship W2523528293A5006813585 @default.
• W2523528293 hasAuthorship W2523528293A5016476418 @default.
• W2523528293 hasAuthorship W2523528293A5021512769 @default.
• W2523528293 hasAuthorship W2523528293A5026900677 @default.
• W2523528293 hasAuthorship W2523528293A5031939021 @default.
• W2523528293 hasAuthorship W2523528293A5049009815 @default.
• W2523528293 hasAuthorship W2523528293A5062529728 @default.
• W2523528293 hasAuthorship W2523528293A5062764108 @default.
• W2523528293 hasAuthorship W2523528293A5066739292 @default.
• W2523528293 hasBestOaLocation W25235282931 @default.
• W2523528293 hasConcept C105702510 @default.
• W2523528293 hasConcept C118487528 @default.
• W2523528293 hasConcept C126322002 @default.
• W2523528293 hasConcept C127413603 @default.
• W2523528293 hasConcept C141071460 @default.
• W2523528293 hasConcept C153074725 @default.
• W2523528293 hasConcept C159985019 @default.
• W2523528293 hasConcept C168563851 @default.
• W2523528293 hasConcept C192562407 @default.
• W2523528293 hasConcept C200990466 @default.
• W2523528293 hasConcept C2776964284 @default.
• W2523528293 hasConcept C2778837293 @default.
• W2523528293 hasConcept C2779553658 @default.
• W2523528293 hasConcept C2780100132 @default.
• W2523528293 hasConcept C42360764 @default.
• W2523528293 hasConcept C71924100 @default.
• W2523528293 hasConceptScore W2523528293C105702510 @default.
• W2523528293 hasConceptScore W2523528293C118487528 @default.
• W2523528293 hasConceptScore W2523528293C126322002 @default.
• W2523528293 hasConceptScore W2523528293C127413603 @default.
• W2523528293 hasConceptScore W2523528293C141071460 @default.
• W2523528293 hasConceptScore W2523528293C153074725 @default.
• W2523528293 hasConceptScore W2523528293C159985019 @default.
• W2523528293 hasConceptScore W2523528293C168563851 @default.
• W2523528293 hasConceptScore W2523528293C192562407 @default.
• W2523528293 hasConceptScore W2523528293C200990466 @default.
• W2523528293 hasConceptScore W2523528293C2776964284 @default.
• W2523528293 hasConceptScore W2523528293C2778837293 @default.
• W2523528293 hasConceptScore W2523528293C2779553658 @default.
• W2523528293 hasConceptScore W2523528293C2780100132 @default.
• W2523528293 hasConceptScore W2523528293C42360764 @default.
• W2523528293 hasConceptScore W2523528293C71924100 @default.
• W2523528293 hasIssue "1" @default.
• W2523528293 hasLocation W25235282931 @default.
• W2523528293 hasLocation W25235282932 @default.
• W2523528293 hasLocation W25235282933 @default.
• W2523528293 hasOpenAccess W2523528293 @default.

• next